Objective
The aim of the “eRaDicate” international, multidisciplinary, and intersectoral cancer drug research and development programme is to empower 10 young scientists to become specialists in cancer research and drug development, while developing new therapies against cancer stem cell-driven relapse and metastasis. Nuclear receptors, such as retinoic acid receptor (RAR) and vitamin D receptor (VDR), play key roles in many hallmarks of cancer and constitute effective targets for modern cancer therapy.
To address the EU priority “Mission Cancer”, we will 1) test the anti-cancer activity of RAR and VDR targeting compounds; 2) design and synthesise a highly innovative dual action hybrid compound acting simultaneously as RARγ antagonist and VDR agonist; 3) devise pre-formulation strategies for our compounds; 4) and develop a novel, deep learning-based cancer analysis and diagnostics method.
We will test how our RAR and VDR-targeting compounds affect stemness and metastatic potential in leukaemia, breast, prostate, colorectal, and ovarian cancer. In parallel, we will assess if the pan-RAR antagonist is effective against chemotherapy-induced neutropenia. For the development of the RAR and VDR targeting compounds into administrable medicines, ready for eventual commercialisation, we will develop pre-formulation strategies. We will generate a novel and highly innovative label-free image analysis method based on histoplasmonic cytometry. The project will have lasting scientific, economic, and societal impact.
In order to be prepared for a wide spectrum of career opportunities, we will train the doctoral candidates (DCs) not only to perform original and independent research on an internationally competitive level, but also endow them with creative, critical and entrepreneurial mindset, coupled with persistence in following their objectives.
Our consortium consists of 8 academic and 1 industrial beneficiary, as well as 12 associated partners to provide training and secondments.
Fields of science
Keywords
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral NetworksCoordinator
1090 Wien
Austria
See on map
Participants (7)
50137 Wroclaw
See on map
84105 Beer Sheva
See on map
15782 Santiago De Compostela
See on map
1020 Wien
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
00-927 WARSZAWA
See on map
02 091 Warszawa
See on map
D02 CX56 DUBLIN 2
See on map
Partners (13)
1030 Wien
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
See on map
Cork
See on map
3500 Krems an der Donau
See on map
3086 La Trobe University
See on map
17489 Greifswald
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
61-614 Poznań
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4001 Brisbane
See on map
30-348 Krakow
See on map
91031 Jerusalem
See on map
M5S 1A1 Toronto
See on map
36078 Valdagno
See on map
B15 2TT Birmingham
See on map